ADC Therapeutics

Youtube Subscribe

Open: 1.51 Close: 1.47 Change: -0.04

What an AI can tell you about ADC Therapeutics Company Inc before investing.

Are looking for the most relevant information about ADC Therapeutics? Investor spend a lot of time searching for information to make investment decisions in ADC Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ADC Therapeutics are: release, beat, estimate, therapy, company, Updated, data, and the most common words in the summary are: therapeutic, inc, payment, unspecified, adc, develop, cancer, . One of the sentences in the summary was: Updated lotis-2 data released to read our press release. Other searches …

Concept Map

Semantic Network

Stock Summary

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA is in Phase II clinical trial for the treatment of.

Today's Summary

Updated LOTIS-2 trial data released. Updated lotis-2 data released to read our press release. CEO Ameet Mallik provided a company update Recording available.

Today's News

Zynlonta (loncastuximab tesirine-lpyl) received the FDA and conditional approval from the European Commission for the treatment of relapsed large B-cell lymphoma after two lines of systemic therapy or refractory therapy. Some optimism remains for the company. Updated LOTIS-2 trial data released. Updated lotis-2 data released to read our press release. CEO Ameet Mallik provided a company update Recording available. J&J beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.58%. ADMA Biologics, Inc. beat estimates and ADMA beat estimates. In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics 2023 loss per share.

Stock Profile

"ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD–dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate ADC Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ADC Therapeutics are: release, beat, estimate, therapy, company, Updated, data, and the most common words in the summary are: therapeutic, inc, payment, unspecified, adc, develop, cancer, . One of the sentences in the summary was: Updated lotis-2 data released to read our press release. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #inc #payment #unspecified #adc #develop #cancer.

Read more →

Youtube Subscribe

---